Quantcast

Latest gastrointestinal stromal tumor Stories

2011-06-05 08:10:00

EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment.

2011-05-20 15:34:00

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S.

2011-05-10 01:30:00

WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S.

2011-04-11 02:00:00

TUEBINGEN, Germany, April 11, 2011 /PRNewswire/ -- immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma. The pivotal Phase III study will evaluate as the primary endpoint...

2011-02-04 01:30:00

WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S.

2010-12-02 05:00:00

NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.

2010-09-27 16:01:00

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc.

2010-08-23 16:01:00

NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc.


Word of the Day
begunk
  • To befool; deceive; balk; jilt.
  • An illusion; a trick; a cheat.
The word 'begunk' may come from a nasalised variant of Scots begeck ("to deceive, disappoint"), equivalent to be- +‎ geck.